Comparative Pharmacology
Head-to-head clinical analysis: ADENOSCAN versus DRONEDARONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSCAN versus DRONEDARONE HYDROCHLORIDE.
ADENOSCAN vs DRONEDARONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is a purine nucleoside that acts as a coronary vasodilator by activating A2A adenosine receptors on vascular smooth muscle, causing hyperemia. It also slows atrioventricular (AV) nodal conduction via A1 receptor activation.
Dronedarone is a benzofuran derivative with antiarrhythmic properties belonging to class III. It blocks multiple ion channels (K+, Na+, Ca2+) and exhibits antiadrenergic effects. It prolongs atrial refractory periods and reduces ventricular rate.
Intravenous administration at 140 mcg/kg/min for 6 minutes (total dose 0.84 mg/kg).
400 mg orally twice daily with meals.
None Documented
None Documented
< 10 seconds (biphasic: distribution half-life < 1 second, terminal elimination half-life ~0.6-1.5 seconds). Clinically, effects are rapidly terminated due to cellular uptake and metabolism.
Terminal half-life is approximately 24 hours (range 13–31 hours) after multiple dosing. Steady state is reached within 4–8 days. The prolonged half-life supports once-daily dosing but requires caution in renal impairment due to accumulation of inactive metabolites.
Primarily renal excretion of metabolites; <3% excreted unchanged in urine. Adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with further degradation to uric acid. <2% eliminated in feces.
Approximately 6% of an oral dose is excreted unchanged in urine. The majority is eliminated as metabolites via biliary excretion into feces (84% of total radioactivity recovered in feces, 6% in urine).
Category C
Category C
Antiarrhythmic
Antiarrhythmic